Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some ...

How a new Trump plan could make science ‘a political football’ The NIH is already in turmoil. Billlions of dol ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...